RHAPSODY Study
Research type
Research Study
Full title
A study to investigate the feasibility of administration of a speech battery and the use of speech-based biomarkers for the clinical assessment of common neurodegenerative and psychiatric disorders in a remote setting.
IRAS ID
283682
Contact name
Allan Young
Contact email
Sponsor organisation
Novoic Limited
Duration of Study in the UK
0 years, 9 months, 30 days
Research summary
The purpose of the RHAPSODY study is to evaluate, in a clinical setting, the ability of speech and language based digital biomarkers and a universal speech test to detect and differentiate between some of the post prevalent neurological and psychiatric disorders.
Participants of all cohorts will take part in a single study visit with a researcher, where they will perform a number of speech tasks, and (depending on the cohort) a number of neurological or psychiatric assessments, questionnaires. All these study visits will be conducted virtually, through a video consultation software.In addition, participants are asked to perform a number of self-assessments (speech tasks and questionnaires) in the one months following their visit. The speech tasks will be audio-recorded and analyzed on Novoic’s technology platform.
REC name
London - Queen Square Research Ethics Committee
REC reference
21/PR/0070
Date of REC Opinion
15 Apr 2021
REC opinion
Further Information Favourable Opinion